Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
ACAAI offers tips to help prevent kids from suffering through allergy and asthma attacks

ACAAI offers tips to help prevent kids from suffering through allergy and asthma attacks

You work hard to keep your child's allergies and asthma under control. You clean to get rid of dust mites and pet dander, and you make sure your kids are taking the right medications at the right time. Then you send them off to school and your routine can fall apart, leaving your child with symptoms that aren't controlled. [More]
UCI molecular biologists find new way to combat skin cancer

UCI molecular biologists find new way to combat skin cancer

Using new and innovative immune-therapeutic approaches to silence "don't eat me" signaling proteins recognized by specialized cells of the immune system, University of California, Irvine molecular biologists and their colleagues have identified an effective way to combat metastatic melanoma. [More]
Roche announces FDA approval of  new VENTANA PD-L1 assay

Roche announces FDA approval of new VENTANA PD-L1 assay

Roche today announced approval of the VENTANA PD-L1 (SP142) Assay by the US Food and Drug Administration as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ™ (atezolizumab) for metastatic urothelial cancer (mUC). [More]
Research could help clinicians identify patients who may benefit from targeted therapy for liver cancer

Research could help clinicians identify patients who may benefit from targeted therapy for liver cancer

New research from Roswell Park Cancer Institute offers clinicians treating patients with advanced liver cancer a way of determining which patients may benefit most from the targeted therapy sorafenib. [More]
T-cell technology could be used to treat ovarian tumors with no adverse effects

T-cell technology could be used to treat ovarian tumors with no adverse effects

With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive. [More]
Resveratrol may be clinically beneficial to people with Alzheimer's disease

Resveratrol may be clinically beneficial to people with Alzheimer's disease

Resveratrol, given to Alzheimer's patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. [More]
New combination treatment improves overall survival in patients with malignant melanoma

New combination treatment improves overall survival in patients with malignant melanoma

Among patients with melanoma, those who received both ipilimumab (Yervoy) and local peripheral treatments such as radiotherapy or electrochemotherapy had significantly prolonged overall survival compared with those who received only ipilimumab, according to a retrospective clinical study. [More]
Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

A drug that blocks neurotransmitters could reduce nausea and vomiting caused by chemotherapy, research co-authored by a Sanford Health physician and published in the New England Journal of Medicine finds. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
New method helps characterize immune cells in tumor tissues

New method helps characterize immune cells in tumor tissues

Despite recent achievements in the development of cancer immunotherapies, only a small group of patients typically respond to them. Predictive markers of disease course and response to immunotherapy are urgently needed. [More]
Cancer immunotherapy could treat HIV

Cancer immunotherapy could treat HIV

A type of immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
New treatment approach may benefit relapsed post-transplant blood cancer patients

New treatment approach may benefit relapsed post-transplant blood cancer patients

For many patients with advanced blood cancers, a stem-cell transplant can drive the disease into remission. However, about one-third of these patients experience a relapse and face a very poor prognosis. [More]
The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute is pleased to announce that the National Institutes of Health has awarded a nearly $23 million Martin Delaney Collaboratories for HIV Cure Research grant to the BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, a consortium of top HIV researchers led by co-principal investigators Luis J. Montaner, D.V.M., D.Phil., director of the HIV-1 Immunopathogenesis Laboratory at The Wistar Institute Vaccine Center, and James L. Riley, Ph.D., research associate professor at the Perelman School of Medicine at the University of Pennsylvania. [More]
UCLA scientists identify mechanisms of tumor resistance to immunotherapy in advanced melanoma

UCLA scientists identify mechanisms of tumor resistance to immunotherapy in advanced melanoma

UCLA researchers have for the first time identified mechanisms that determine how advanced melanoma can become resistant to immune checkpoint inhibitors, a discovery that could lead to the development of new and improved treatments for the deadliest type of skin cancer. [More]
Two new studies find potential genetic cause and new treatment method for autoimmune diseases

Two new studies find potential genetic cause and new treatment method for autoimmune diseases

The American Autoimmune Related Diseases Association, Inc. is spotlighting two new research studies originally reported in ScienceDaily. [More]
Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget. [More]
Study shows how increase in BMI contributes to multiple myeloma growth and progression

Study shows how increase in BMI contributes to multiple myeloma growth and progression

In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients. [More]
Immunotherapy cancer trials presented to key opinion leaders

Immunotherapy cancer trials presented to key opinion leaders

Immodulon recently met with some of the world’s most renowned oncologists to present their forthcoming trials for immunotherapy treatment, IMM-101. [More]
UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors. [More]
Advertisement
Advertisement